The U.S. Food and Drug Administration may soon curtail the use of two monoclonal antibody treatments that do not appear to work against the highly contagious Omicron variant.
The treatments made by Regeneron and Eli Lilly performed well against earlier variants, but only GlaxoSmithKline’s antibody therapy has stayed strong against Omicron.
Last week, the National Institutes of Health updated its guidelines to advise clinics against using these treatments on patients with mild to moderate COVID-19 due to their diminished effectiveness.
